{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:02:06Z","timestamp":1785535326308,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1139466"],"award-info":[{"award-number":["APP1139466"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.leukres.2024.107504","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T16:25:45Z","timestamp":1713975945000},"page":"107504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34+ and CD3+ donor chimerism (DC) monitoring"],"prefix":"10.1016","volume":"142","author":[{"given":"Tishya","family":"Indran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongted","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Muirhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Cirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Widjaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.leukres.2024.107504_bib1","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.leukres.2024.107504_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2014-02-514760","article-title":"Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist","volume":"124","author":"Kekre","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2024.107504_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2024.107504_bib4","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2024.107504_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2024.107504_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.leukres.2024.107504_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12907-017-0066-8","article-title":"Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach","volume":"17","author":"Courville","year":"2017","journal-title":"BMC Clin. Pathol."},{"issue":"7","key":"10.1016\/j.leukres.2024.107504_bib8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.bbmt.2016.03.023","article-title":"Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant","volume":"22","author":"Motabi","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"19","key":"10.1016\/j.leukres.2024.107504_bib9","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.3390\/ijms241915019","article-title":"Novel approaches to treatment of acute myeloid leukemia relapse post allogeneic stem cell transplantation","volume":"24","author":"Liberatore","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.leukres.2024.107504_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00277-017-3185-5","article-title":"Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI\u2014a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"97","author":"Schroeder","year":"2018","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107504_bib11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2024.107504_bib12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbmt.2012.12.013","article-title":"Outcome of donor lymphocyte infusion after T cell\u2013depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes","volume":"19","author":"Krishnamurthy","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.leukres.2024.107504_bib13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41409-019-0695-x","article-title":"Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)","volume":"55","author":"Feliu","year":"2020","journal-title":"Bone Marrow Transpl."},{"issue":"9","key":"10.1016\/j.leukres.2024.107504_bib14","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00277-021-04494-z","article-title":"Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis","volume":"100","author":"Rettig","year":"2021","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107504_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/asheducation-2014.1.570","article-title":"Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions","volume":"2014","author":"Nikiforow","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2024.107504_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2016.12.004","article-title":"Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect","volume":"48","author":"Orti","year":"2017","journal-title":"Exp. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107504_bib17","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3324\/haematol.2009.007765","article-title":"Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation","volume":"94","author":"Bornh\u00e4user","year":"2009","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.leukres.2024.107504_bib18","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2020.07.013","article-title":"Early mixed lymphoid donor\/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis","volume":"26","author":"Deeg","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2024.107504_bib19","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1182\/blood-2020-143465","article-title":"Peripheral blood CD34+ donor chimerism is superior to CD3+ donor chimerism for predicting relapse following allogeneic stem cell transplantation for myeloid malignancies","volume":"136","author":"Das","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107504_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/tan.14557","article-title":"Utility of assessing CD3+ cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia","volume":"100","author":"Bendjelloul","year":"2022","journal-title":"HLA"},{"issue":"5","key":"10.1016\/j.leukres.2024.107504_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/bmt.2014.2","volume":"49","author":"Solomon","year":"2014","journal-title":"Bone Marrow Transpl."},{"issue":"10","key":"10.1016\/j.leukres.2024.107504_bib22","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1002\/cam4.3763","article-title":"Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with\/without decitabine for prophylaxis of relapse after allogeneic HSCT: a pilot study","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.leukres.2024.107504_bib23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.V73.6.1729.1729","article-title":"Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial","volume":"73","author":"Storb","year":"1989","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107504_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/asheducation-2018.1.228","article-title":"Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation","volume":"2018","author":"Hamilton","year":"2018","journal-title":"Hematology"},{"issue":"31","key":"10.1016\/j.leukres.2024.107504_bib25","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:42:43Z","timestamp":1720222963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":25,"alternative-id":["S0145212624000705"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107504","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34+ and CD3+ donor chimerism (DC) monitoring","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107504"}}